Vaccination Plus Ontak in Patients With Metastatic Melanoma

Stopped The immune monitoring data failed to demonstrate an improvement in any biologic endpoint with denileukin diftitox.

Conditions

• Melanoma

Interventions

• BIOLOGICAL: 4-peptide melanoma vaccine
• DRUG: Ontak

Sponsor

University of Chicago

Collaborators

• [object Object]